Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposomes + capecitabine
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Irinotecan liposomes + capecitabine is a combination chemotherapy regimen being investigated for the neoadjuvant treatment of locally advanced rectal cancer (LARC). Irinotecan liposome is a nanoparticle formulation of irinotecan, a topoisomerase I inhibitor, encapsulated in a lipid bilayer vesicle to enhance tumor delivery and prolong systemic circulation. Capecitabine is an oral fluoropyrimidine prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, where it inhibits thymidylate synthase. In a Phase I study led by Zhejiang Cancer Hospital, this combination is administered concurrently with radiotherapy. A key feature of this regimen's development is the use of genotype-driven dosing, where the dose of irinotecan liposomes is stratified based on the patient's UGT1A1 *28 and *6 polymorphisms to optimize safety and manage potential dose-limiting toxicities such as neutropenia and diarrhea.
- Other names
- irinotecan liposome injection + capecitabinenanoliposomal irinotecan + capecitabine
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on irinotecan liposomes + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposomes + capecitabine.